MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Novavax Inc

Closed

SectorHealthcare

5.61 -6.81

Overview

Share price change

24h

Current

Min

5.35

Max

5.97

Key metrics

By Trading Economics

Income

40M

-81M

Sales

3.8M

88M

EPS

-0.52

Profit margin

-91.755

Employees

952

EBITDA

52M

-53M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+146.66% upside

Dividends

By Dow Jones

Next Earnings

9 May 2025

Market Stats

By TradingEconomics

Market Cap

-140M

1.1B

Previous open

12.42

Previous close

5.61

News Sentiment

By Acuity

93%

7%

372 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Novavax Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Apr 2025, 17:06 UTC

Major Market Movers

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status

31 Mar 2025, 14:19 UTC

Major Market Movers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

4 Feb 2025, 18:52 UTC

Major Market Movers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

11 Nov 2024, 14:05 UTC

Major Market Movers

Novavax to Move Forward With Covid-19, Influenza Vaccine After FDA Lifts Clinical Hold

16 Oct 2024, 12:59 UTC

Major Market Movers

Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines; Shares Drop

13 May 2024, 18:14 UTC

Major Market Movers

Novavax Shares Pop Another 50% Following Sanofi Deal

10 May 2024, 10:59 UTC

Major Market Movers

Novavax Shares Surge on $1.4 Billion Vaccine Licensing Deal with Sanofi

30 Dec 2024, 23:02 UTC

Acquisitions, Mergers, Takeovers

Novavax Completes Previously Announced $200M Sale of Czech Republic Manufacturing Site to Novo Nordisk

4 Dec 2024, 07:09 UTC

Acquisitions, Mergers, Takeovers

Novavax: Agreement to Close by Dec 30 >NVAX

4 Dec 2024, 07:08 UTC

Acquisitions, Mergers, Takeovers

Novavax: Sale Aligns With Plan to Become More Lean Organization, Drive Value From Pipeline Assets & Tech Platform >NVAX

4 Dec 2024, 07:07 UTC

Acquisitions, Mergers, Takeovers

Novavax: Deal to Also Reduce Annual Operating Costs by About $80M >NVAX

4 Dec 2024, 07:06 UTC

Acquisitions, Mergers, Takeovers

Novavax to Get $190M Cash Payment in 2024, Additional $10M in 2025 >NVAX

4 Dec 2024, 07:06 UTC

Acquisitions, Mergers, Takeovers

Novavax: Agreement Provides Company With Significant, Non-Dilutive Capital >NVAX

4 Dec 2024, 07:04 UTC

Acquisitions, Mergers, Takeovers

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200M

15 Nov 2024, 13:34 UTC

Top News

Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too -- WSJ

15 Nov 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

16 Oct 2024, 15:22 UTC

Earnings

These Stocks Are Moving the Most Today: ASML, Nvidia, Morgan Stanley, United Airlines, DJT, Novavax, J.B. Hunt, Cisco, and More -- Barrons.com

10 May 2024, 20:11 UTC

Earnings

These Stocks Moved the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, Gen Digital, JFrog, SoundHound, and More -- Barrons.com

10 May 2024, 14:49 UTC

Earnings
Hot Stocks

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

10 May 2024, 10:47 UTC

Acquisitions, Mergers, Takeovers

Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps. -- Barrons.com

Peer Comparison

Price change

Novavax Inc Forecast

Price Target

By TipRanks

146.66% upside

12 Months Forecast

Average 14.75 USD  146.66%

High 19 USD

Low 9 USD

Based on 4 Wall Street analysts offering 12 month price targets forNovavax Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

N/A / 7.011Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

372 / 386 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.